Vericel Corporation - Common Stock (VCEL)
58.35
-1.35 (-2.26%)
Vericel Corporation is a biotechnology company that focuses on developing and commercializing innovative, cell-based products for a variety of medical needs
Specializing in regenerative medicine, Vericel primarily addresses the treatment of diseases and conditions affecting the skin and cartilage. Their flagship products are designed to enhance healing and improve patient outcomes, particularly in areas such as sports medicine and burn care. Through its commitment to research and development, Vericel aims to transform the treatment landscape for patients with complex medical needs.
![](https://cdn.benzinga.com/files/images/story/2025/01/15/movers-image_9.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 15, 2025
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Via Investor's Business Daily · November 11, 2024
![](https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg)
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Via Talk Markets · November 7, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/02/Chengdu--China---Mar-10--2020-Apple-Stor_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 2, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga · July 16, 2024
![](https://talkmarkets.com/images/logos/talkmarkets.png)
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
Via Talk Markets · July 1, 2024
![](https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600.png)
Are you looking for highly-rated medical stocks? These three contenders are offering substantial growth over the long term.
Via InvestorPlace · June 27, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Via Benzinga · May 9, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Frontline (NYSEFRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via Benzinga · February 29, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Via Benzinga · January 16, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
VCEL stock results show that Vericel beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
![](https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg)
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.
Via Talk Markets · March 11, 2024
![](https://investorplace.com/wp-content/uploads/2020/07/pharma-stocks.jpg)
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
Via InvestorPlace · February 26, 2024
![](https://cdn.benzinga.com/files/images/story/2023/12/28/mdwd_co.png?width=1200&height=800&fit=crop)
Biopharmaceutical company MediWound Ltd (NASDAQMDWD) reported that the U.S.
Via Benzinga · December 28, 2023
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600b.jpg)
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
Via InvestorPlace · November 16, 2023
![](https://investorplace.com/wp-content/uploads/2023/07/growth-stock-red-paper-airplane-1600.jpg)
These 3 strong buy stocks have industry experts' positive outlook and seal of approval. The only question is, are you in?
Via InvestorPlace · November 10, 2023
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Flex LNG (NYSEFLNG) is estimated to report earnings for its third quarter.
Via Benzinga · November 8, 2023